NCT02517528View on ClinicalTrials.gov

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

PHASE3CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

July 20, 2015

Primary Completion Date

September 29, 2016

Study Completion Date

March 16, 2017

Conditions
Chronic Hepatitis C Virus (HCV)
Interventions
DRUG

ABT-450/r/ABT-267

Tablet

DRUG

ABT-333

Tablet

DRUG

ribavirin

Tablet

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY

NCT02517528 - ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis | Biotech Hunter | Biotech Hunter